Business Wire

Data Virtualization Can Deliver ROI of 408% According to New Independent Research Study

1.12.2021 11:00:00 EET | Business Wire | Press release

Share

Denodo, the leader in data virtualization, today revealed the findings of a new Total Economic Impact™ (TEI) study to demonstrate the tangible benefits of data virtualization using the Denodo Platform. The study, commissioned by Denodo and conducted by Forrester Consulting, quantified the financial impact of the solution and found Denodo customers achieved a return on investment of 408% and total economic benefits of a present value up to $6.8 million over three years.

The complete, complimentary study can be found here.

More specifically, the benefits to a blended organization that consists of long term Denodo customers include:

  • 83% reduction in time-to-revenue
  • 67% reduction in data preparation effort
  • 65% decrease in delivery times over ETL

According to the TEI study, “Data fabric technology takes the data virtualization a step further by automating data management functions using artificial intelligence/machine learning (AI/ML) and providing additional semantic capabilities through data catalog, data preparation, and data modeling. This reduces the burden on IT and data engineering teams that traditionally leveraged ETL processes.”

The TEI study is a culmination of Forrester’s multi-step approach to evaluating the financial impact of the Denodo Platform by interviewing several of Denodo's longest standing customers. To better understand the benefits, costs, and risks associated with this investment, Forrester interviewed key decision-makers across four companies in different industries with experience using the Denodo Platform. The highlights from their investments include:

  • Decrease in data delivery times over ETL: “Since deploying Denodo, we have gone anywhere from a couple of days or weeks to less than a day to deliver data sets.” - IT Manager, Manufacturing
  • Improved operational efficiency enabled with data-driven decision-making: “From the [operations] perspective, being able to provide business users with the capability to start asking and answering questions themselves … it has really given us the ability to see around the corner. There is no way that my team, even if we dropped everything, would have been able to react to a situation like the pandemic as fast as we did without Denodo.” - VP of Data & Analytics, Real Estate
  • Improved profit: “Let’s say it took our data science team three months to write this model for a project, and now we can get that down to one week, we are increasing the probability that the project succeeds as opposed to slowing it down and we can release our product sooner. These are multimillion dollar products, so even delaying them one day can be a million dollars or more in missed revenue.” – Director, Enterprise Architecture, Life Sciences Industry
  • Reduced legacy integration costs & efficiency gain for data scientists: “In terms of reducing legacy spending, we’re probably saving $400,000 a year. The flip side of that is Denodo has allowed us to do a lot more so now, we’ve grown that footprint and we’ve replaced that $400,000 with a whole bunch of new things we can never do in the old world. More importantly, our data scientists no longer spend 30% of their time on data wrangling and data curation. They can now spend that time on modeling since we can logically model our data within Denodo.” - VP of Data & Analytics, Real Estate

Data virtualization helps organizations access data across disparate sources and deliver a unified view of the data faster, cheaper, and using fewer resources than traditional data integration approaches. Denodo’s logical data fabric approach goes beyond data virtualization, enabling organizations to effectively integrate and manage their data where it lives without replicating it, allowing both technical and non-technical users to quickly answer key business questions using a data-driven approach.

“With retention rates close to 95%, the Denodo Platform goes beyond every other data virtualization solution enabling organizations to connect to all of their data in real time at half the cost of traditional approaches,” said Ravi Shankar, senior vice president and chief marketing officer at Denodo. “We believe this comprehensive Forrester study demonstrates the power and ROI potential organizations can achieve by leveraging the Denodo Platform, as we help bridge the gap between IT and business.”

For more information, download the study here.

Please Tweet: News: @denodo delivers ROI of 408% according to new independent research study @forrester Total Economic Impact™ study showcases the benefits of Denodo’s #datavirtualization solution to create a logical #datafabric and how it enables customers to rapidly increase business agility and performance https://bit.ly/3xCkvZ4

About Denodo

Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chris McCoin or Richard Smith
McCoin & Smith Communications Inc.
508-429-5988 (Chris) or 978-433-3304 (Rick)
chris@mccoinsmith.com or rick@mccoinsmith.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AIM Expands Life Sciences Supply Chain Capabilities and Hires New Partner, Thomas Ebel1.6.2026 16:01:00 EEST | Press release

AIM today announced the appointment of veteran pharma supply chain expert Thomas Ebel as Partner, effective June 15. Mr. Ebel brings more than 25 years of supply chain consulting experience at leading firms including CAMELOT, McKinsey, and Accenture, and will anchor a broader initiative to expand AIM’s end-to-end supply chain capabilities. According to Richard de Bakker, Statutory Director and Founder at AIM, the firm is significantly expanding its capabilities around “end-to-end” supply chain needs. “AIM is well known as a leader in supply chain development for launch, as well as optimization of existing supply chains — supporting clients in getting their finished products to patients,” said Mr. de Bakker. “We are now adding new capabilities in supply chain diagnostics and strategy, end-to-end planning optimization, supply reliability, and working capital optimization, among others. Combined with AIM’s established supply chain expertise, this expanded offering gives clients true ‘end-

Seoul Semiconductor's World-First 'HV Opto-Semiconductor' Powers Up Global Top 4 Automakers1.6.2026 16:00:00 EEST | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890), a global opto-semiconductor technology company, announced that its world's first High Voltage (HV) opto-semiconductor technology has entered mass production with four of the world's top automotive brands across the Americas, Europe, and Asia, with plans to expand supply to 10 models by the end of the year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601232986/en/ Comparison: Conventional 3V LED vs. Seoul Semiconductor 12V 'HV Opto-Semiconductor' (Figure: Seoul Semiconductor) The technology combines micro-scaled opto-semiconductor chips capable of 12V single-chip operation — as opposed to conventional 3V LEDs — with a high-voltage (HV) driver technology. This enables a reduction of more than 10% in the number of driver-related components used in hybrid and electric vehicles, while lowering power consumption by approximately 10%, contributing to cost reduction and simplific

Oscilloquartz delivers assured timing for mission-critical harsh environments with ruggedSync ™ Series OSA 55101.6.2026 15:00:00 EEST | Press release

Oscilloquartz today launched its ruggedSync™ Series OSA 5510, a ruggedized timing and synchronization platform engineered for defense and other harsh, mission-critical environments. Designed for deployment in tactical communications networks, mobile command centers (MCCs), aviation systems and other highly demanding operational environments, the OSA 5510 combines PTP grandmaster and NTP server functionality with synchronization assurance and resilient holdover in a compact MIL-qualified platform. Multi-band GNSS support, encrypted and authenticated timing options and environmental protection enable operation in contested and GNSS-denied environments where trusted synchronization must be maintained. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601763766/en/ Oscilloquartz’s ruggedSync™ Series OSA 5510 delivers resilient, high-precision timing for mission-critical defense networks. “Our new ruggedSync™ Series OSA 5510 exte

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy1.6.2026 15:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026. If approved, povetacicept will become the first commercialized therapy in Vertex’s emerging nephrology franchise. “The Phase 3 RAINIER trial is the largest conducted in IgAN and achieved full enrollment faster than any contemporary IgAN trial, reflecting the significant unmet need in IgAN and our urgency to bring povetacicept to patients with this serious disease,” said Nia Tatsis, Ph.D., Executive Vice President and Chief Regulatory and Quality Officer at Vertex. “With today’s FDA accepta

Winston Taylor Completes Historic Transatlantic Combination1.6.2026 14:01:00 EEST | Press release

Winston Taylor announces today that Winston & Strawn and Taylor Wessing’s U.K.-led business have officially launched as a single combined firm, creating a premier transatlantic law firm built for the needs of the businesses, people, and markets driving capital and innovation. One of the largest transatlantic firms, with more than 1,400 lawyers spanning the United States, the United Kingdom, Europe, Latin America, and the Middle East, Winston Taylor is built to meet clients’ evolving global needs for counsel. “As Winston Taylor, we are centered on a client-first approach and will be working shoulder to shoulder with our clients at the cutting edge of industry and ingenuity,” said Chairman Steve D’Amore. “With that common purpose, we are leveraging both strength and scale by integrating our teams and offices at record speed, working at pace to create a firm that is aligned, focused, and built for the day-to-day needs of our clients as well as their breakthrough moments.” Winston Taylor o

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye